Clinical Significance of Lipoprotein Particles

  • J. C. Fruchart
  • J. M. Bard
  • C. Fievet
  • P. Duriez
  • P. Puchois


Apolipoproteins, the protein components of the lipoproteins have a variety of structural and metabolic roles related to the metabolism of lipids. They are involved in determining the transfer of lipids from one lipoprotein particle to another and act as cofactors, activators and inhibitors of enzymes involved in the synthesis and degradation of lipoprotein particles (1). Additionally, the apolipoproteins are necessary for the recognition by cell-surface receptor sites which specifically promote the catabolism of the various lipoprotein fractions (2).


Lipoprotein Particle Weak Reactor Cholesterol Acyl Transferase Human Apolipoprotein Epitope Expression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mahley RW, Innerarity TL, Rail SC, Weisgraber KH. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res 1984; 25: 1277–1291.Google Scholar
  2. 2.
    Gianturco SH, Via DP, Gotto AM, Bradley WA. Lipoproteins receptors. Role of receptors in biology and medicine, 1986; 219/16: 167–192.Google Scholar
  3. 3.
    Alaupovic P. The physicochemical and immunological heterogeneity of human plasma high-density lipoproteins. In: Miller NE, Miller GJ, eds. Clinical and Metabolic Aspects of High-Density Lipoproteins. Amsterdam: Elseviers Science Publishers, 1984.Google Scholar
  4. 4.
    Alaupovic P. The concepts, classification systems and nomenclature of human plasma lipoproteins. In: Lewis LA, Opplt JJ, eds. Lipoproteins: Basic Principles and Concepts. Boca Raton, Florida: CRC Press, Inc, 1980.Google Scholar
  5. 5.
    Fruchart JC, Fievet C, Puchois P. Apo-lipoproteins. In: Bergmeyer HU, ed. Methods of Enzymatic Analysis. Weinheim: VCH, 1985.Google Scholar
  6. 6.
    Fruchart JC. Polyclonal, oligoclonal and monoclonal antibody mapping of lipoprotein particles. In: Fidge NH, Nestel PJ, eds. Atherosclerosis VII. Elseviers Science Publishers B.V., 1986.Google Scholar
  7. 7.
    Gesquière JC, Delpierre C, Tartar A, Cachera C, Equagoo K, Fruchart JC. Synthetic peptides as alternative antigens in the production of antibodies against human apolipoproteins. Clin Chem 1985; 31/5: 784.Google Scholar
  8. 8.
    Koren E, Puchois P, Alaupovic P, Fesmire J, Kandoussi A, Fruchart JC. Quantification of two different types of apolipoprotein A-I containing lipoprotein particles in plasma by enzyme-linked differential-antibody immunosorbent assay. Clin Chem 1987; 33: 38–43.Google Scholar
  9. 9.
    Duriez P, Vu Dac N, Koffigan M, et al. Detection of human apolipoprotein B polymorphic species with one monoclonal antibody (BIP 45) against low density lipoprotein. Atherosclerosis 1987; in press.Google Scholar
  10. 10.
    Barbaras R, Puchois P, Fruchart JC, Ailhaud G. Cholesterol efflux from cultured adipose cells is mediated by LpA-I particles but not by LpA-I:A-II particles. Biochem Biophys Res Commun 1987; 142/1: 63–69.CrossRefGoogle Scholar
  11. 11.
    Puchois P, Kandoussi A, Fievet P, et al. Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis 1987; in press.Google Scholar
  12. 12.
    Cheung MC, Wolf AC, Blum KD, Tollepson JH, Albers JJ. Distribution and localization of lecithin: cholesterol acyltransferase and cholesteryl ester transfer activity in A-I containing lipoproteins. J Lipid Res 1986; 27: 1135.Google Scholar
  13. 13.
    Ferrence RG, Truscott S, Whitehead PC. Drinking and the prevention of coronary heart disease: findings, issues and public health policy. J Studies Alcohol 1986: 47/5.Google Scholar
  14. 14.
    Puchois P, Ghalim N, Demarquilly C, Zylberberg G, Fruchart JC. Effect of alcohol consumption on lipoprotein particles which contain apo A-I and apo A-II (LpA-I:A-II) and apo A-I but not A-II (LpA-I). The American Heart Association’s, 59th Scientific Sessions, Dallas, 17–20 novembre 1986. Circulation 1986; 74/111: 383.Google Scholar
  15. 15.
    Fruchart JC, Davignon J, Bard JM, Grothe AM, Richard A, Fievet C. Effect of fenofibrate treatment on type III hyperlipoproteinemia. Am J Med 1987; in press.Google Scholar
  16. 16.
    Fruchart JC, Fievet C, Bard JM, et al. Effect of fenofibrate on lipoprotein particles predictive of coronary atherosclerosis. IX International Symposium on Drugs Affecting Lipid Metabolism, Florence, 22–25 octobre 1986; in press.Google Scholar
  17. 17.
    Parsy D, Dracon M, Cachera C, et al. Lipoprotein abnormalities in chronic hemodialysis patients. Nephrology Dialysis Transplantation 1987; in press.Google Scholar
  18. 18.
    Duriez P, Butler R, Tikkanen MJ, et al. A monoclonal antibody (BIP 45) detects AG (c, g) polymorphism of human apolipoprotein B. J Immunol Meth 1987; in press.Google Scholar
  19. 19.
    Salmon S, Goldstein S, Pastier D, et al. Monoclonal antibodies to low density lipoprotein used for the study of low- and very-low-density lipoproteins, in “ELISA” and immunoprecipitation technics. Biochem Biophys Res Commun 1984; 125/2: 704–711.CrossRefGoogle Scholar
  20. 20.
    Fievet C, Demarquilly C, Luyeye I, Fievet P, Moschetto Y, Fruchart JC. Utilisation d’anticorps polyclonaux et monoclonaux pour le dépistage de l’athérosclérose. Intérêt de nouveaux marqueurs. Ann Biol Clin 1985; 43/4: 500–504.Google Scholar
  21. 21.
    Albert A, Chappele JP. Stepwise probit discrimination with specific application to short-term prognosis in acute myocardial infarction. Comput Biomed Res 1981; 14: 391–398.CrossRefGoogle Scholar
  22. 22.
    Fruchart JC, Parra H, Kandoussi A, Fievet C, Lablanche JM, Bertrand M. Monoclonal antibody mapping of lipoprotein particles in the prediction of coronary atherosclerosis. The American Heart Association’s, 58th Scientific Sessions, Washington, 11–14 novembre 1985. Circulation 1985; 72/4: 92.Google Scholar
  23. 23.
    Barkia A, Martin C, Puchois P, et al. Enzyme linked immunosorbant assay for human proapolipoprotein A-I using specific antibodies against synthetic peptide. J Lipid Res 1987; in press.Google Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • J. C. Fruchart
    • 1
    • 2
  • J. M. Bard
    • 1
    • 2
  • C. Fievet
    • 1
    • 2
  • P. Duriez
    • 1
    • 2
  • P. Puchois
    • 1
    • 2
  1. 1.Institut PasteurSERLIALille CédexFrance
  2. 2.Faculté de PharmacieDépartement Lipides Lipoprotéines et U. INSERM 279Lille CédexFrance

Personalised recommendations